BD to Announce Financial Results for its First Quarter of Fiscal 2026
Rhea-AI Summary
BD (NYSE: BDX) will host an audio webcast at 8:00 a.m. ET on Monday, February 9, 2026 to discuss financial results for its first quarter of fiscal 2026 (period ended December 31, 2025) and to provide an update on operations and strategy. Prior to the call, the company will issue a news release and presentation materials including summary financial information.
The live audio webcast and subsequent replay will be available at www.bd.com/investors.
Positive
- None.
Negative
- None.
News Market Reaction – BDX
On the day this news was published, BDX declined 0.01%, reflecting a mild negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Jan 23 | AI product launch | Positive | -2.1% | Global launch of BD Research Cloud 7.0 with AI panel design tools. |
| Jan 21 | Partnership expansion | Positive | +1.4% | Expanded Ypsomed partnership for 5.5 mL Neopak XtraFlow syringe platform. |
| Jan 15 | Regulatory clearance | Positive | +0.5% | FDA 510(k) clearance for EnCor EnCompass breast biopsy system. |
| Jan 14 | Leadership change | Positive | +2.9% | Appointment of Shawn Bevec as senior vice president of investor relations. |
| Jan 13 | Capacity investment | Positive | -0.6% | $110 million investment to expand U.S. Neopak syringe production capacity. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent operational and strategic announcements have generally seen modest, mixed price reactions, with some positive news followed by both gains and pullbacks.
This announcement sets the date for BD’s first-quarter fiscal 2026 results following an active January. Recent news included an FDA 510(k) clearance for the EnCor EnCompass breast biopsy system, a $110 million U.S. manufacturing investment, and an expanded biologics-focused partnership with Ypsomed. BD also launched its BD Research Cloud 7.0 AI-driven platform and appointed a new senior vice president of investor relations. Price reactions to these developments have ranged from about -2% to +3%, indicating varied market responses.
AI-generated analysis. How Rhea-AI works. Not financial advice.
About BD
BD is one of the largest global medical technology companies in the world and is advancing the world of health by improving medical discovery, diagnostics and the delivery of care. The company supports the heroes on the frontlines of health care by developing innovative technology, services and solutions that help advance both clinical therapy for patients and clinical process for health care providers. BD and its more than 70,000 employees have a passion and commitment to help enhance the safety and efficiency of clinicians' care delivery process, enable laboratory scientists to accurately detect disease and advance researchers' capabilities to develop the next generation of diagnostics and therapeutics. BD has a presence in virtually every country and partners with organizations around the world to address some of the most challenging global health issues. By working in close collaboration with customers, BD can help enhance outcomes, lower costs, increase efficiencies, improve safety and expand access to health care. For more information on BD, please visit bd.com or connect with us on LinkedIn at www.linkedin.com/company/bd1/, X (formerly Twitter) @BDandCo or Instagram @becton_dickinson.
Contacts: | |
Media: | Investors: |
Matt Marcus | Shawn Bevec |
VP, Public Relations | SVP, Investor Relations |
View original content:https://www.prnewswire.com/news-releases/bd-to-announce-financial-results-for-its-first-quarter-of-fiscal-2026-302671314.html
SOURCE BD (Becton, Dickinson and Company)